Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
Ludwig Heesen(Uppsala University Hospital), Uğur Şahin(Johannes Gutenberg University Mainz), Andreas N. Kuhn(Uppsala University Hospital), Sebastian Kreiter(Johannes Gutenberg University Mainz), Klaus Kühlcke(Institute of Bioinformatics and Systems Biology), Stefanie Bolte(BioNTech (Germany)), Katrin Frenzel(Uppsala University Hospital), K. Thielemans, Evelyna Derhovanessian(University of Tübingen), Henrik Lindman(Uppsala University), M. Schmidt(Johannes Gutenberg University Mainz), Ture Sjoblom(Uppsala University), Laurence Zitvogel(Institut Gustave Roussy), Valesca Bukur(Uppsala University Hospital), Mustafa Diken, Steve Pascolo(University of Zurich), Özlem Türeci(Johannes Gutenberg University Mainz), Andreas Schneeweiß(German Cancer Research Center), M. Löwer
Cited by 4
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k